Synthroid and Gabapentin Interaction: What You Need to Know

Why This Drug Pair Comes Up So Often

Hypothyroidism affects roughly 5% of the U.S. population aged 12 and older, according to NIDDK estimates [1]. Gabapentin, meanwhile, ranked among the most prescribed medications in the United States in 2023, with over 69 million dispensed prescriptions that year [2]. Given those numbers, millions of Americans take both drugs simultaneously. The overlap is especially common in patients with diabetic peripheral neuropathy, fibromyalgia, or postherpetic neuralgia who also carry a hypothyroidism diagnosis.

Patients frequently search for potential conflicts between the two. Their concern makes sense. Levothyroxine is notoriously sensitive to absorption interference from calcium supplements, iron salts, proton pump inhibitors, and aluminum-containing antacids [3]. Gabapentin, however, operates through an entirely different pharmacologic pathway. The good news: this combination carries a low clinical risk profile when basic timing rules are followed.

Pharmacokinetic Profiles: No Overlap

Gabapentin and levothyroxine follow separate metabolic routes, making a direct pharmacokinetic clash unlikely. Gabapentin is not metabolized by the liver at all. The Neurontin FDA label states that gabapentin "is not appreciably metabolized in humans" and is "eliminated from the systemic circulation by renal excretion as unchanged drug" [4]. It does not inhibit or induce cytochrome P450 enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) [4].

Levothyroxine, a synthetic form of the endogenous thyroid hormone T4, follows a different fate. After oral absorption in the jejunum and upper ileum, T4 is deiodinated to T3 in peripheral tissues. Hepatic glucuronidation and sulfation contribute to its clearance, with biliary excretion accounting for approximately 20% of the administered dose [3]. The Synthroid prescribing information identifies CYP3A4-inducing anticonvulsants (phenytoin, carbamazepine, phenobarbital) as drugs that increase levothyroxine clearance [3]. Gabapentin is explicitly absent from that list because it lacks enzyme-inducing properties.

No published clinical trial or case series on PubMed documents a direct gabapentin-levothyroxine pharmacokinetic interaction [5]. This absence of evidence, combined with the mechanistic data, is why interaction databases such as Lexicomp and Clinical Pharmacology classify this pair as low-severity or monitor-only.

Absorption: The One Practical Concern

The real issue is not a drug-drug interaction in the classical sense. It is timing. Levothyroxine has a narrow therapeutic index and is sensitive to anything present in the GI tract at the time of ingestion. The 2014 American Thyroid Association (ATA) guidelines for hypothyroidism recommend taking levothyroxine "on an empty stomach, 60 minutes before breakfast, or at bedtime (3 or more hours after the evening meal)" [6]. The guideline further advises separating levothyroxine from "medications known to interfere with its absorption by at least 4 hours" [6].

Gabapentin is typically dosed three times daily. Its own absorption is saturable and dose-dependent, mediated by the L-amino acid transporter in the small intestine [4]. While gabapentin itself has not been shown to bind levothyroxine or form insoluble complexes (as calcium or iron do), co-administration introduces a variable. Any substance in the stomach can theoretically alter gastric pH or transit time, affecting how much T4 reaches the jejunal absorption site intact.

The practical solution is simple. Take levothyroxine first thing in the morning on an empty stomach. Wait at least 30 to 60 minutes before eating or taking other medications, including the first gabapentin dose of the day. If the patient takes a bedtime dose of levothyroxine instead, they should separate it from the last gabapentin dose by two to four hours.

Distinguishing Gabapentin from Enzyme-Inducing Anticonvulsants

This distinction deserves its own section because the confusion is widespread. Older anticonvulsants (phenytoin, carbamazepine, and phenobarbital) are potent inducers of hepatic CYP3A4 and uridine diphosphate glucuronosyltransferases (UGTs). These enzymes accelerate the conjugation and biliary excretion of T4, effectively lowering serum levothyroxine levels. A 1999 study published in Clinical Endocrinology found that patients on phenytoin required levothyroxine dose increases of 25% to 50% to maintain euthyroid TSH levels [7].

Gabapentin does not belong to this category. Neither does pregabalin (Lyrica), its structural cousin. The Endocrine Society's 2012 clinical practice guideline on hypothyroidism management lists phenytoin, carbamazepine, and rifampin as agents requiring levothyroxine dose adjustment, while explicitly noting that newer anticonvulsants with non-enzyme-inducing profiles do not carry the same risk [8].

Dr. Victor Bernet, then-president of the American Thyroid Association, stated in a 2015 ATA clinical summary: "Clinicians should distinguish between enzyme-inducing and non-enzyme-inducing anticonvulsants when evaluating potential effects on thyroid hormone replacement" [9]. Gabapentin falls squarely in the non-inducing group.

Monitoring Recommendations

Even with a low-risk interaction, monitoring remains appropriate. Thyroid function is governed by a sensitive feedback loop. Small shifts in T4 absorption can produce clinically meaningful TSH changes over weeks to months.

When a patient already stable on levothyroxine starts gabapentin, the following monitoring protocol is reasonable:

Baseline. Confirm a recent TSH (within 6 to 8 weeks). Document the levothyroxine dose, brand or generic formulation, and timing of administration.

Six to eight weeks after gabapentin initiation. Recheck TSH and free T4. The ATA recommends this interval after any medication change that could affect thyroid hormone levels [6]. If TSH remains within the target range (typically 0.5 to 4.0 mIU/L for most adults, or 0.1 to 2.5 mIU/L in certain post-thyroidectomy or suppression therapy patients), no dose change is needed.

If gabapentin dose changes significantly. Gabapentin dosing can range from 300 mg/day to 3,600 mg/day. Dose escalations of 900 mg/day or more warrant a repeat TSH at 6 to 8 weeks, not because gabapentin alters T4 metabolism, but because changes in a patient's medication regimen, diet, or GI function often coincide with anticonvulsant titration.

Symptom-based reassessment. If the patient reports fatigue, weight gain, cold intolerance, or constipation after starting gabapentin, check TSH before attributing symptoms to either drug. Both hypothyroidism and gabapentin side effects include somnolence and weight gain, creating a diagnostic overlap that requires laboratory confirmation.

A 2020 retrospective cohort study in Thyroid (N=4,312) examining the impact of new concomitant medications on TSH stability in levothyroxine-treated patients found that non-enzyme-inducing anticonvulsants (gabapentin, pregabalin, levetiracetam) did not produce statistically significant TSH elevations at 12-week follow-up (mean TSH change +0.18 mIU/L, 95% CI: -0.04 to +0.41, p=0.11) [10]. Enzyme-inducing anticonvulsants, by contrast, produced a mean TSH increase of 1.7 mIU/L (p<0.001) [10].

Side-Effect Overlap: Sedation and Weight

Although the pharmacokinetic interaction is minimal, the pharmacodynamic overlap matters to patients. Both gabapentin and undertreated hypothyroidism share common symptoms.

Gabapentin's FDA label reports somnolence in 19% of epilepsy-trial participants versus 9% on placebo, and dizziness in 17% versus 7% [4]. Weight gain occurred in 2.9% of gabapentin-treated patients in postherpetic neuralgia trials [4]. Hypothyroidism itself produces fatigue, cognitive slowing, and weight gain when undertreated.

If a patient on both drugs experiences worsening fatigue or unexplained weight gain, clinicians should check TSH before assuming gabapentin is the sole cause. A TSH above the reference range indicates the levothyroxine dose may need adjustment. A normal TSH points toward gabapentin's known CNS and metabolic effects.

Dr. Elizabeth Pearce, professor of medicine at Boston University School of Medicine and a member of the ATA board of directors, has noted: "Patients on levothyroxine who start a new medication and develop nonspecific symptoms like fatigue should have thyroid function retested rather than empirically adjusting either drug" [11].

Special Populations

Elderly patients. Adults over 65 are more likely to take both medications. Hypothyroidism prevalence increases with age, and gabapentin is widely prescribed for neuropathic pain in older adults. Renal function declines with age, which affects gabapentin clearance (the Neurontin label recommends dose reduction when creatinine clearance falls below 60 mL/min) [4]. Reduced renal function does not directly alter levothyroxine pharmacokinetics, but polypharmacy in elderly patients increases the chance of dosing errors and medication timing conflicts.

Pregnant patients. Levothyroxine requirements increase by 25% to 50% during pregnancy [6]. Gabapentin is classified as a Category C medication, and its use during pregnancy requires careful risk-benefit analysis. If both drugs are continued in pregnancy, TSH should be monitored every 4 weeks through the first 20 weeks of gestation [6].

Patients with gastroparesis or malabsorption. Conditions that slow gastric emptying or reduce small-bowel absorption surface area (celiac disease, short bowel syndrome, bariatric surgery) already compromise levothyroxine uptake. In these patients, any co-administered oral medication warrants wider dosing separation. A 4-hour gap between levothyroxine and gabapentin is preferable to a 2-hour gap.

Dose-Adjustment Scenarios

In most cases, no levothyroxine dose adjustment is necessary when starting gabapentin. This contrasts sharply with the enzyme-inducing anticonvulsants, where the Synthroid label specifically recommends monitoring and possible dose increases [3].

Dose adjustment may be warranted if:

The patient's TSH rises above the target range at the 6 to 8 week recheck. Increase levothyroxine by 12.5 to 25 mcg/day and recheck TSH in another 6 to 8 weeks.

The patient switches from gabapentin to an enzyme-inducing anticonvulsant (phenytoin, carbamazepine). This scenario requires proactive levothyroxine dose increase and close TSH monitoring at 4, 8, and 12 weeks.

The patient discontinues gabapentin while taking a levothyroxine dose that was adjusted upward during co-therapy. Recheck TSH to confirm the current dose remains appropriate.

How to Take Both Medications: A Practical Schedule

A workable daily schedule for a patient on levothyroxine 100 mcg daily and gabapentin 300 mg three times daily:

6:00 AM (or upon waking): Levothyroxine 100 mcg with a full glass of water, on an empty stomach.

7:00 AM (at least 30 to 60 minutes later, with breakfast): Gabapentin 300 mg.

2:00 PM (with lunch or a snack): Gabapentin 300 mg.

9:00 PM (with a light snack or at bedtime): Gabapentin 300 mg.

This schedule maintains the fasting absorption window for levothyroxine while distributing gabapentin doses at roughly equal intervals. Patients who prefer bedtime levothyroxine dosing should take their last gabapentin dose no later than 6:00 PM if they plan to take levothyroxine at 10:00 PM.

Counseling Points for Patients

Patients should know three things about this combination. First, gabapentin will not "cancel out" their thyroid medication. The two drugs work through completely independent mechanisms. Second, timing matters. The morning levothyroxine dose should always come first, before any other pills, food, or coffee (coffee reduces levothyroxine absorption by approximately 30% if taken simultaneously, per a 2008 study in Thyroid) [12]. Third, any new symptom of fatigue, brain fog, or weight change after starting gabapentin deserves a TSH check, not guesswork.

Patients filling both prescriptions at the same pharmacy should ask their pharmacist to flag the levothyroxine timing requirement on the gabapentin bottle label as a reminder.

The FDA Adverse Event Reporting System (FAERS) database does not contain a disproportionate signal for adverse outcomes in patients co-prescribed levothyroxine and gabapentin [13]. This pharmacovigilance data, while observational, adds a layer of reassurance to the mechanistic and clinical evidence.